Coleman Jon 4

What Happened

Jon Coleman, Executive Vice President and Chief Commercial Officer of DexCom, Inc. (DXCM), was granted 43,897 restricted stock units (RSUs) on March 8, 2026. The grant is reported at an acquisition price of $0.00 (awarded, not purchased) and represents a contingent right to receive one share of common stock per RSU upon vesting. The filing notes a total of 112,635 unvested RSUs associated with Coleman, including the 43,897 granted on March 8, 2026 and 68,738 granted on May 22, 2025.

Key Details

• Transaction date: March 8, 2026; Form 4 filed March 10, 2026 (timely filing).
• Transaction type/code: A — Award/Grant; reported price $0.00; reported value $0.
• Vesting: RSUs vest in three equal annual installments from the grant date (per footnote).
• Unvested RSUs after grant (aggregate disclosed): 112,635 total — 43,897 (granted 3/8/2026, vest through 3/8/2029) and 68,738 (granted 5/22/2025, vest through 5/22/2029).
• Footnotes: F1 describes the RSU award and three-year vesting; F2 details the breakdown of the 112,635 unvested RSUs. Exhibit 24 = Power of Attorney.
• No indication of sales, purchases, tax withholding, or 10b5-1 plan in this filing.

Context

RSUs are equity awards (not open-market purchases) giving the holder a right to receive shares if and when they vest; they do not necessarily indicate immediate bullish or bearish insider intent. These RSUs are exempt as described in the filing (footnote) and will convert to actual shares only as they vest according to the schedule.